-logo-1200x675.png?v=20220303080937){kind=logo}
The Oncology Institute, Inc. (NASDAQ:TOI – Get Free Report) insider Yale Podnos sold 23,451 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the transaction, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oncology Institute Trading Down 2.2%
TOI opened at $4.96 on Wednesday. The company has a 50 day moving average of $3.86 and a 200 day moving average of $3.41. The company has a market cap of $490.25 million, a PE ratio of -13.41 and a beta of 0.37. The Oncology Institute, Inc. has a 12 month low of $2.02 and a 12 month high of $5.57.
Oncology Institute (NASDAQ:TOI – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. The business had revenue of $147.44 million during the quarter, compared to the consensus estimate of $142.10 million. Research analysts forecast that The Oncology Institute, Inc. will post -0.17 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Institutional Trading of Oncology Institute
Several institutional investors and hedge funds have recently made changes to their positions in TOI. Kestra Advisory Services LLC purchased a new stake in shares of Oncology Institute during the 4th quarter valued at $31,000. Pekin Hardy Strauss Inc. purchased a new stake in shares of Oncology Institute during the 4th quarter valued at $36,000. Cetera Investment Advisers raised its position in shares of Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after buying an additional 4,545 shares in the last quarter. State of Wyoming purchased a new stake in shares of Oncology Institute during the 2nd quarter valued at $37,000. Finally, R Squared Ltd purchased a new stake in shares of Oncology Institute during the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.
About Oncology Institute
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
Featured Stories
- Five stocks we like better than Oncology Institute
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
